CoChat

The DOI matches its Crossref record; 166 of the 166 references it cites were found in a registry or an index.

Presynaptic antiseizure medications-basic mechanisms and clues for their rational combinations

Open access

Abstract

Among clinically highly efficient antiseizure medications (ASMs) there are modifiers of the presynaptic release machinery. Of them, levetiracetam and brivaracetam show a high affinity to the synaptic vesicle protein type 2 A (SV2A), whereas pregabalin and gabapentin are selective ligands for the α2δ1 subunits of the voltage-gated calcium channels. In this paper, we present recent progress in understanding the significance of presynaptic release machinery in the neurochemical mechanisms of epilepsy and ASMs. Furthermore, we discuss whether the knowledge of the basic mechanisms of the presynaptically acting ASMs might help establish a rational polytherapy for drug-resistant epilepsy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s43440-024-00603-7

Cites

166 of 166 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 The main neuronal targets of racetams and gabapentinoids (inspired by the figure in the paper by Bialer and White [166])
Fig. 1 The main neuronal targets of racetams and gabapentinoids (inspired by the figure in the paper by Bialer and White [166])CC BY · PubMed Central
Fig. 2 Isobolograms illustrating interactions between gabapentin and pregabalin in the 6 Hz corneal stimulation-induced seizure (A) and maximal electroshock-induced (MES) seizure (B) tests in mice. A. The type I isobolographic analysis was used to assess the interactions between two fully effective drugs in the mouse 6 Hz test (A). The isobologram for the combination of two fully active drugs, pregabalin and gabapentin in the 6 Hz test was presented earlier [77], and partly modified to display isobolographically areas of synergy, additivity and antagonism, where the experimentally derived ED50 mix value can be placed. The ED50 values for pregabalin and gabapentin when used alone in the 6 Hz test are placed on the ordinate (Y) and abscissa (X) of the Cartesian plot system of coordinates, respectively. The line connecting these ED50 values on the X and Y axes is the line of additivity. The diagonal line starting from the beginning of the Cartesian plot system and crossing the line of additivity indicates the proportion of the two-drug mixture (at the fixed-ratio of 1:1). For the interaction of pregabalin with gabapentin in the 6 Hz test, the experimentally derived ED50 mix (as the point M on the graph) is placed in the area of additivity, close to the point A, which reflects the theoretically calculated ED50 add value, predicted to exert additive interaction between drugs. B. The type II isobolographic analysis was conducted to evaluate the interaction between drugs of which gabapentin was ineffective in the mouse MES test (B). The isobologram for the combination of pregabalin (a fully active drug) and gabapentin (a virtually ineffective drug) in the MES test was presented earlier [130], and partly modified to display isobolographically areas of synergy, additivity and antagonism, where the experimentally derived ED50 mix value can be placed. The ED50 value for pregabalin when used alone in the mouse MES test is placed on the ordinate of the Cartesian plot system of coordinates. The line parallel to X axis starting from the ED50 for pregabalin is the line of indifference (additivity). The diagonal lines starting from the beginning of the Cartesian plot system and crossing the line of additivity indicate the proportions of the drugs in the mixture (at the fixed-ratios of 1:1, 1:2 and 1:4). For the interaction of pregabalin with gabapentin in the MES test, the experimentally derived ED50 mix (as the point M on the graph for the fixed-ratio of 1:1) is placed in the area of synergy, significantly below the area of additivity (*p < 0.05), which reflects the theoretically calculated ED50 add value, predicted to exert additive interaction between drugs
Fig. 2 Isobolograms illustrating interactions between gabapentin and pregabalin in the 6 Hz corneal stimulation-induced seizure (A) and maximal electroshock-induced (MES) seizure (B) tests in mice. A. The type I isobolographic analysis was used to assess the interactions between two fully effective drugs in the mouse 6 Hz test (A). The isobologram for the combination of two fully active drugs, pregabalin and gabapentin in the 6 Hz test was presented earlier [77], and partly modified to display isobolographically areas of synergy, additivity and antagonism, where the experimentally derived ED50 mix value can be placed. The ED50 values for pregabalin and gabapentin when used alone in the 6 Hz test are placed on the ordinate (Y) and abscissa (X) of the Cartesian plot system of coordinates, respectively. The line connecting these ED50 values on the X and Y axes is the line of additivity. The diagonal line starting from the beginning of the Cartesian plot system and crossing the line of additivity indicates the proportion of the two-drug mixture (at the fixed-ratio of 1:1). For the interaction of pregabalin with gabapentin in the 6 Hz test, the experimentally derived ED50 mix (as the point M on the graph) is placed in the area of additivity, close to the point A, which reflects the theoretically calculated ED50 add value, predicted to exert additive interaction between drugs. B. The type II isobolographic analysis was conducted to evaluate the interaction between drugs of which gabapentin was ineffective in the mouse MES test (B). The isobologram for the combination of pregabalin (a fully active drug) and gabapentin (a virtually ineffective drug) in the MES test was presented earlier [130], and partly modified to display isobolographically areas of synergy, additivity and antagonism, where the experimentally derived ED50 mix value can be placed. The ED50 value for pregabalin when used alone in the mouse MES test is placed on the ordinate of the Cartesian plot system of coordinates. The line parallel to X axis starting from the ED50 for pregabalin is the line of indifference (additivity). The diagonal lines starting from the beginning of the Cartesian plot system and crossing the line of additivity indicate the proportions of the drugs in the mixture (at the fixed-ratios of 1:1, 1:2 and 1:4). For the interaction of pregabalin with gabapentin in the MES test, the experimentally derived ED50 mix (as the point M on the graph for the fixed-ratio of 1:1) is placed in the area of synergy, significantly below the area of additivity (*p < 0.05), which reflects the theoretically calculated ED50 add value, predicted to exert additive interaction between drugsCC BY · PubMed Central
Fig. 3 Two proposed methods of clinical evaluation of drug combinations.A. Method 1 assumes the ineffectiveness of drug A at the maximum tolerated dose and a therapeutic success after adding the minimum effective dose of drug B (first step), an unsuccessful attempt at discontinuing drug A (second step) and a repeated therapeutic success after reinstating drug A but at the minimum effective dose (third step). B. Method 2 assumes a partial effectiveness of drug A used at a high dose and a therapeutic success after adding a minimal effective dose of drug B (first step) and the maintenance of the said effect after lowering the dose of the first drug without attempting to discontinue its administration (step two)
Fig. 3 Two proposed methods of clinical evaluation of drug combinations.A. Method 1 assumes the ineffectiveness of drug A at the maximum tolerated dose and a therapeutic success after adding the minimum effective dose of drug B (first step), an unsuccessful attempt at discontinuing drug A (second step) and a repeated therapeutic success after reinstating drug A but at the minimum effective dose (third step). B. Method 2 assumes a partial effectiveness of drug A used at a high dose and a therapeutic success after adding a minimal effective dose of drug B (first step) and the maintenance of the said effect after lowering the dose of the first drug without attempting to discontinue its administration (step two)CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 166 references

Cited by

See all 17

Metadata

Authors
Czapińska-Ciepiela, E. K., Łuszczki, J., Czapiński, P., Czuczwar, S. J., & Lasoń, W.
Affiliations
  • Medical University of Lublin (PL)
  • Maj Institute of Pharmacology (PL)
Corresponding author
Lasoń, Władysław
Venue
Pharmacological Reports
Published
2024-05-22
Volume
76
Issue
4
Pages
623-643
ISSN
  • 1734-1140 (ISSN-L)
  • 2299-5684
OpenAlex
W4398219983
Cited by
13
References
166
Citations by year
2026: 10 · 2025: 3
FWCI
1.04
Type
journal article
Language
en
Open access
Licence
Locations
  • Pharmacological Reports (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmacological Effects and Toxicity Studies
Keywords
levetiracetam, brivaracetam, pregabalin, gabapentin, α2δ-1 subunit, voltage-gated calcium channels, epilepsy, drug-resistant epilepsy, combination therapy
MeSH terms
Animals, Anticonvulsants, Epilepsy, Humans, Calcium Channels, Presynaptic Terminals

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Presynaptic antiseizure medications-basic mechanisms and clues for their rational combinations. https://app.cochat.ai/papers/10.1007/s43440-024-00603-7
The paper
Czapińska-Ciepiela, E. K., Łuszczki, J., Czapiński, P., Czuczwar, S. J., & Lasoń, W. (2024). Presynaptic antiseizure medications-basic mechanisms and clues for their rational combinations. Pharmacological Reports. https://doi.org/10.1007/s43440-024-00603-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.